Pureos Bioventures is a venture capital firm that focuses on early-stage investments in the life sciences sector, particularly in therapeutic start-ups developing innovative treatments for serious diseases.

Klaus Breiner

Dominik Escher

Martin Münchbach

Pureos Bioventures

Pureos Bioventures is a venture capital fund, which invests exclusively in private innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug formats. The fund’s portfolio companies are built on scientific excellence to develop therapies across a broad indication spectrum including oncology, immunology, ophthalmology, rare diseases, and
neuroscience. Pureos has built a team with deep investment, operating and clinical expertise, that strives to impact patients’ lives by advancing innovative treatments for devastating diseases.

Corlieve Therapeutics

Lava Therapeutics

Acrivon Therapeutics

Our portfolio company VICO Therapeutics B.V. closed their Series B financing of EUR 54mn to advance the clinical development of their lead program VO659 in spinocerebellar ataxia types 3 and 1 and Huntington’s disease.
Congratulations to the team!
 
We are looking forward continuing the journey to bring innovation to patients with rare neurological disease.

https://lnkd.in/eiQ2xBX4

Our portfolio company LAVA Therapeutics N.V. announces a collaboration with Merck & Co., Inc. to evaluate Lava-1207 in combination with pembrolizumab. This cooperation will support the initiation of a combination arm in the ongoing Phase 1/2a trial in patients with prostate cancer (mCRPC).
We are looking forward continuing the journey to bring new therapies to patients with mCRPC.

https://lnkd.in/eBNc9ZjA 

Pureos Bioventures portfolio company AM-Pharma started testing ilofotase alfa, as a preventive treatment for cardiac surgery-associated renal damage in a clincal Phase 2 study. A high medical need indication. Fingers crossed that ilofotase will help to prevent CSA-RD!

https://lnkd.in/eykpXE5R

Start your year with listening to the latest episode of The Drug Discovery World Podcast! Manfred Ruediger, CEO of our portfolio company Ariceum Therapeutics talks about their pipeline of radiopharmaceutical drugs for cancer patients and the future for the company.
 
Do not miss:
https://lnkd.in/eGcPJwGK

Metric
Company Name	Pureos Bioventures
Symbol
MSH ID	COM:PUREOSBIO
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Venture Capital
Country	CH
Stage
Employee Count	14
Website	pureosbio.com
LinkedIn	pureos-bioventures
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	1.25K
Web Traffic Growth	-0.06
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:PUREOSBIO

Pureos Bioventures

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue